文献速递造血干细胞移植与细胞治疗

激素难治性或依赖性急性移植物抗宿主病血液生物标志物的预后价值:REACH2分析

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis.
PubMed 文献 · Blood · 2023-01-01

REACH2三期试验的探索性分析开发了基线和第14天模型,评估12种aGVHD相关细胞因子/趋化因子、6种免疫细胞类型和3种炎症蛋白对第28天缓解概率的影响。芦可替尼治疗、预处理、皮肤受累和年龄与缓解可能性增加相关,基线多数标志物水平较低与缓解概率增加相关;第14天模型中第14天标志物水平而非基线变化影响缓解概率,两模型偏倚校正AUC分别为0.73和0.80。

要点

  • 芦可替尼治疗、预处理、皮肤受累和年龄在至少一个模型中与缓解可能性增加强烈相关
  • 基线多数aGVHD和免疫细胞标志物水平较低与缓解概率增加相关
  • 第14天模型中第14天标志物水平而非基线变化影响缓解概率,AUC为0.80

核心结论

  • 所选生物标志物和患者特征可能具有预后价值。

研究设计与样本

  • REACH2三期试验(NCT02913261)的探索性分析(首个生物标志物研究),开发基线和第14天模型评估12种aGVHD相关细胞因子/趋化因子、6种免疫细胞类型和3种炎症蛋白对第28天缓解概率的影响。

主要发现

  • 芦可替尼治疗、预处理、皮肤受累和年龄在至少一个模型中与缓解可能性增加强烈相关。
  • 基线多数aGVHD和免疫细胞标志物水平较低与缓解概率增加相关。
  • 第14天模型中第14天aGVHD标志物水平而非基线变化影响缓解概率。
  • 基线模型偏倚校正AUC为0.73,第14天模型为0.80,提示拟合与实际结局高度对应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic steroids are the standard first-line treatment for acute graft-versus-host disease (aGVHD), but ∼50% of patients become steroid-refractory or dependent (SR/D). Ruxolitinib is the only Food and Drug Administration- and European Medicines Agency-approved therapy for patients with SR/D aGVHD. In the phase 3 REACH2 trial (NCT02913261), ruxolitinib demonstrated superior efficacy in SR/D aGVHD, with a significantly higher overall response rate (ORR) on day 28, durable ORR on day 56, and longer median overall survival compared with the best available therapy (BAT). Identifying biomarkers and clinical characteristics associated with increased probability of response can guide treatment decisions. In this exploratory analysis of the REACH2 study (first biomarker study), we developed baseline (pretreatment) and day 14 models to identify patient characteristics and biomarkers (12 aGVHD-associated cytokines/chemokines, 6 immune cell types, and 3 inflammatory proteins) before and during treatment, which affected the probability of response at day 28. Treatment with ruxolitinib, conditioning, skin involvement, and age were strongly associated with an increased likelihood of response in the ≥1 model. Lower levels of most aGVHD and immune cell markers at baseline were associated with an increased probability of response. In the day 14 model, levels of aGVHD markers at day 14, rather than changes from baseline, affected the probability of response. For both models, the bias-corrected area under the receiver operating characteristic values (baseline, 0.73; day 14, 0.80) indicated a high level of correspondence between the fitted and actual outcomes. Our results suggest potential prognostic value of selected biomarkers and patient characteristics.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Socié G, Niederwieser D, von Bubnoff N, et al. Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis. Blood. 2023. PMID: 36827620. doi:10.1182/blood.2022018579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。